Company intelligence / Profile preview

OphtiMed Rx

Ownership: Private
Development stage: Preclinical

Overview

OphtiMed Rx has developed a highly potent compound that protects retinal cells from senescence, aiming to halt disease progression in early-intermediate dry AMD. The approach has shown promising results both in vivo and in vitro and represents a novel strategy to address the root cause of dry AMD by targeting cellular aging processes. The company’s technology could potentially prevent blindness and reduce the socioeconomic burden associated with this condition.

Therapeutic areas: Ophthalmology
Modalities: Small molecules (novel molecular therapy targeting cellular senescence)
Industry: Biotech

Drug pipeline

1 asset

OM-301

Preclinical

Partnerships

Supported by Galil Ofek Ventures, Mor Research Applications, RunYoung organization; strategic funding from Israel Innovation Authority and Women TechEU grant.

Beyond the preview

Go deeper on OphtiMed Rx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OphtiMed Rx.

Explore the full profile